Immune response to E7 protein of human papillomavirus type 16 anchored on the cell surface

Cancer Immunology, Immunotherapy

Volumn 51, Issue 2, 2002, Pages 111-119

  Němečková, A Aárka ^a   Stránská, Růžena ^a,b,c   Šubrtová, Jana ^a,b,c   Kutinová, Luda ^a,b,c   Otáhal, Pavel ^a,b,c   Hainz, Petr ^a,b,c   Marešová, Lucie ^a,b,c   Šroller, Vojtěch ^a,b,c   Hamšíková, Eva ^a,b,c   Vonka, Vladimír ^a,b,c  

^a INSTITUTE OF HEMATOLOGY AND BLOOD TRANSFUSION   (Czech Republic)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c UNIVERSITY OF IOWA   (United States)

Author keywords

Antibody; Cellular immunity; E7; Hemagglutinin; HPV16; Protein targeting; Vaccinia virus

Indexed keywords

HPV16E7; HYBRID PROTEIN; IMMUNOGLOBULIN G; PROTEIN E7; RECOMBINANT DNA; UNCLASSIFIED DRUG; VIRUS HEMAGGLUTININ; VIRUS PROTEIN;

AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY PRODUCTION; ANTIBODY SPECIFICITY; ARTICLE; CELL SURFACE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; FUSION GENE; GENE CONSTRUCT; GENE EXPRESSION; IMMUNE RESPONSE; MOUSE; NONHUMAN; PAPILLOMA VIRUS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN STABILITY; PROTEIN TARGETING; TH1 CELL; TUMOR GROWTH; VACCINIA VIRUS; VIRUS RECOMBINANT; VIRUS STRAIN;

ANIMALS; ANTIBODIES, VIRAL; HEMAGGLUTININS, VIRAL; IMMUNITY, CELLULAR; INTERLEUKIN-4; MICE; MICE, INBRED C57BL; NEOPLASMS, EXPERIMENTAL; ONCOGENE PROTEINS, VIRAL; RABBITS; RECOMBINANT FUSION PROTEINS; VACCINATION; VACCINIA VIRUS; VIRAL VACCINES;

EID: 0036123013     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-001-0261-3     Document Type: Article

References (32)

1. Phenotypic analysis of antigen-specific T lymphocytes
2. The immunogenicity of VP7, a rotavirus antigen resident in the endoplasmic reticulum, is enhanced by cell surface expression
3. Antigen expression by dendritic cells correlates with the therapeutic effectiveness of a model recombinant poxvirus tumor vaccine
4. Vaccinia virus expression vector: Coexpression of beta-galactosidase provides visual screening of recombinant virus plaques
5. Recombinant DNA vaccines protect against tumors that are resistant to recombinant vaccinia vaccines containing the same gene
6. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papilloma-virus type 16-transformed cells
7. Expression of a functional single chain antibody on the surface of extracellular enveloped vaccinia virus as a step towards selective tumour cell targeting
8. The complete DNA sequence of vaccinia virus
9. Biogenesis of poxviruses: Interrelationship between hemagglutinin production and polykaryocytosis
10. Molecular cloning of a membrane-associated human FK506- and rapamycin-binding protein, FKBP-13
11. Antibodies against the human papillomavirus type 16 early proteins in human sera: Correlation of anti-E7 reactivity with cervical cancer
12. The purification of four strains of poxvirus
13. Synthetic peptides derived from E7 region of human papillomavirus type 16 used as antigens in ELISA
14. Hepatitis B virus proteins expressed by recombinant vaccinia viruses: Influence of preS2 sequence on expression surface and nucleocapsid proteins in human diploid cells
15. Search for optimal parent for recombinant vaccinia virus vaccines. Study of three vaccinia virus vaccinal strains and several virus lines derived from them
16. Effect of virulence on immunogenicity of single and double vaccinia virus recombinants expressing differently immunogenic antigens: Antibody-response inhibition induced by immunization with a mixture of recombinants differing in virulence
17. Anchoring a secreted Plasmodium antigen on the surface of recombinant vaccinia virus-infected cells increases its immunogenicity
18. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen
19. IFN-gamma-independent IgG2a production in mice infected with viruses and parasites
20. Metabolism of cells in tissue culture in vitro. I. The influence of serum protein fractions on the growth of normal and neoplastic cells
21. Human papillomavirus and cervical cancer: Epidemiological evidence
22. Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety
23. Insertion and deletion mutants of vaccinia virus
24. Degradation of the E7 human papillomavirus onco-protein by the ubiquitin-proteasome system: Targeting via ubiquitination of the N-terminal residue
25. + T cells
26. Interleukin-4 mediates down regulation of antiviral cytokine expression and cytotoxic T-lymphocyte responses and exacerbates vaccinia virus infection in vivo
27. A "public" T-helper epitope of the E7 transforming protein of human papillomavirus 16 provides cognate help for several E7 B-cell epitopes from cervical cancer-associated human papillomavirus genotypes
28. Targeting of HIV-1 antigens for rapid intracellular degradation enhances cytotoxic T lymphocyte (CTL) recognition and the induction of de novo CTL responses in vivo after immunization
29. Normal rat cell lines deficient in nuclear thymidine kinase
30. Defective presentation to class I-restricted cytotoxic T lymphocytes in vaccinia-infected cells is overcome by enhanced degradation of antigen
31. Addition of the MSA1 signal and anchor sequences to the malaria merozoite surface antigen 1 C-terminal region enhances immunogenicity when expressed by recombinant vaccinia virus